A phase II trial of piroxantrone in endometrial cancer: Southwest Oncology Group Study 8918

Anti-Cancer Drugs

Volumn 7, Issue 5, 1996, Pages 527-530

  Malviya, Vinay K ^a   Liu, P Y ^b   Goldberg, David A ^c   Hantel, Alexander ^d   O'Toole, Robert V ^e   Roach, Ralph W ^f   Conrad, Marcel E ^g   Alberts, David S ^h  

^a WAYNE STATE UNIVERSITY   (United States)

^b SW Oncology Group Statistical Center ^*  (United States)

^c Atlanta Regional CCOP   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f Columbus CCOP ^*  (United States)

^g UNIVERSITY OF SOUTH ALABAMA   (United States)

^h UNIVERSITY OF ARIZONA   (United States)

Author keywords

advanced endometrial cancer; piroxantrone; recurrent endometrial cancer

Indexed keywords

OXANTHRAZOLE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; ENDOMETRIUM CARCINOMA; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0029795170     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199607000-00006     Document Type: Article

References (10)

1. Showalter HDH, Johnson JL, Werbel LM, Weoplold WR, Jackson RC, Eislager EF. 5-[(Aminoalkyl)aminol-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anti-cancer agents. Synthesis and biological evaluation. J Med Chem 1984; 27: 253-55.
2. Fagan MA, Hacker MP, Newman RA. Cardiotoxic potential of the anthrapyrazoles. Proc Am Ass Cancer Res 1984; 25: 302.
3. Fry DW, Boritzky TJ, Besserer JA, Jackson RC. In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9 cd]pyrazol-6(2H)-ones (anthrapyrazoles). Biochem Pharmacol 1985; 34: 3499-508.
4. Frank SK, Mathiesen DA, Szurszewski M, Kuffel JF, Ames MM. Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174, piroxantrone). Cancer Chemother Pharmacol 1989; 23: 213-8.
5. Sebolt J, Havlick M, Hamelehle K, Klohs WD, Steinkampf RW, Jackson RC. Established of Adriamycin-resistant mammary adenocarcinoma 16/C in vitro and its sensitivity to the anthrapyrazoles CI-942 and CI-937. Proc Am Ass Cancer Res 1985; 26; 339.
6. Loepold W, Nelson J, Plowman J, Jackson RC. Anthrapyrazoles, a new class of interacting agents with high level broad spectrum activity against marine tumors. Cancer Res 1985, 85: 5532-39.
7. Ames MM, Loprinzi CL, Collins JM et al. Phase I and clinical pharmacological evaluation of piroxantrone hydrochloride (oxantrazole). Cancer Res 1990; 50: 3905-9.
8. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-53.
9. Savarese DMF, Denicoff A, Berg S et al. Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor. J Clin Oncol 1993; 11: 1795-803.
10. Hantel A, Donehower RC, Rowinsky EK et al. Phase I study and pharmacodynamics of piroxantrone, a new anthrapyrazole. Cancer Res 1990; 50: 3284-8.